chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: joint pain three weeks after first dose; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (joint pain three weeks after first dose) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ETANERCEPT (ENBREL) for an unknown indication.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced ARTHRALGIA (joint pain three weeks after first dose). At the time of the report, ARTHRALGIA (joint pain three weeks after first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no treatment drugs were provided.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Contusion, Formication, Inappropriate schedule of product administration, Pain of skin
Clinical narrative: Bruising on right shoulder/Bruising on back; Skin of back hurt; Feels like sunburn; something is moving on her back; Missed 2nd dose of Moderna vaccine on recommended interval; Lot of pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of CONTUSION (Bruising on right shoulder/Bruising on back), PAIN OF SKIN (Skin of back hurt), BURNING SENSATION (Feels like sunburn), FORMICATION (something is moving on her back) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed 2nd dose of Moderna vaccine on recommended interval) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 009C21A and 009D21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included GABAPENTIN, HYDROXYZINE EMBONATE (HYDROXYZINE PAM) and DESVENLAFAXINE SUCCINATE MONOHYDRATE (PRISTIQ) for an unknown indication.   On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CONTUSION (Bruising on right shoulder/Bruising on back), PAIN OF SKIN (Skin of back hurt), BURNING SENSATION (Feels like sunburn), FORMICATION (something is moving on her back), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed 2nd dose of Moderna vaccine on recommended interval) and VACCINATION SITE PAIN (Lot of pain at injection site). The patient was treated with IBUPROFEN for Adverse event, at a dose of UNK dosage form. At the time of the report, CONTUSION (Bruising on right shoulder/Bruising on back), PAIN OF SKIN (Skin of back hurt), BURNING SENSATION (Feels like sunburn), FORMICATION (something is moving on her back), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed 2nd dose of Moderna vaccine on recommended interval) and VACCINATION SITE PAIN (Lot of pain at injection site) had resolved.            It was reported that the patient consulted 2 dermatologists for the events.   This case was linked to MOD-2021-213231 (dose 2 case) (Patient Link).
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Bruising on right shoulder/Bruising on back; Skin of back hurt; Feels like sunburn; something is moving on her back; Missed 2nd dose of Moderna vaccine on recommended interval; Lot of pain at injection site; This spontaneous case was reported by a consumer and describes the occurrence of CONTUSION (Bruising on right shoulder/Bruising on back), PAIN OF SKIN (Skin of back hurt), BURNING SENSATION (Feels like sunburn), FORMICATION (something is moving on her back) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed 2nd dose of Moderna vaccine on recommended interval) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 009C21A and 009D21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included GABAPENTIN, HYDROXYZINE EMBONATE (HYDROXYZINE PAM) and DESVENLAFAXINE SUCCINATE MONOHYDRATE (PRISTIQ) for an unknown indication.   On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced CONTUSION (Bruising on right shoulder/Bruising on back), PAIN OF SKIN (Skin of back hurt), BURNING SENSATION (Feels like sunburn), FORMICATION (something is moving on her back), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed 2nd dose of Moderna vaccine on recommended interval) and VACCINATION SITE PAIN (Lot of pain at injection site). The patient was treated with IBUPROFEN for Adverse event, at a dose of UNK dosage form. At the time of the report, CONTUSION (Bruising on right shoulder/Bruising on back), PAIN OF SKIN (Skin of back hurt), BURNING SENSATION (Feels like sunburn), FORMICATION (something is moving on her back), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed 2nd dose of Moderna vaccine on recommended interval) and VACCINATION SITE PAIN (Lot of pain at injection site) had resolved.            It was reported that the patient consulted 2 dermatologists for the events.   This case was linked to MOD-2021-213231 (dose 2 case) (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Product administration interrupted
Clinical narrative: more than 35 days since received first dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (more than 35 days since received first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-May-2021, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (more than 35 days since received first dose). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (more than 35 days since received first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported . No treatment medication was reported .
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chest pain, Diarrhoea, Myalgia, Post procedural complication
Clinical narrative: chest pain; loose bowel movements; Symptoms have gotten progressively worse; muscle pain / new muscle pains; Joint pain three weeks after first dose; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (chest pain), MYALGIA (muscle pain / new muscle pains), DIARRHOEA (loose bowel movements), ARTHRALGIA (Joint pain three weeks after first dose) and POST PROCEDURAL COMPLICATION (Symptoms have gotten progressively worse) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026A21A and 002B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included ETANERCEPT (ENBREL) for an unknown indication.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 02-Apr-2021, the patient experienced ARTHRALGIA (Joint pain three weeks after first dose). On 08-Jun-2021, the patient experienced MYALGIA (muscle pain / new muscle pains). On an unknown date, the patient experienced CHEST PAIN (chest pain), DIARRHOEA (loose bowel movements) and POST PROCEDURAL COMPLICATION (Symptoms have gotten progressively worse). The patient was treated with PREDNISONE ongoing from 02-Jun-2021 at a dose of 20 mg. At the time of the report, CHEST PAIN (chest pain), MYALGIA (muscle pain / new muscle pains), DIARRHOEA (loose bowel movements), ARTHRALGIA (Joint pain three weeks after first dose) and POST PROCEDURAL COMPLICATION (Symptoms have gotten progressively worse) outcome was unknown.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: out of the 42 day interval range; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (out of the 42 day interval range) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (out of the 42 day interval range). At the time of the report, PRODUCT DOSE OMISSION ISSUE (out of the 42 day interval range) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that the patient was currently 48 days post first dose. No concomitant medications provided. No treatment information provided.
Sex: U
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: missed 2nd dose of the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (missed 2nd dose of the vaccine) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (missed 2nd dose of the vaccine). At the time of the report, PRODUCT DOSE OMISSION ISSUE (missed 2nd dose of the vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was reported that the patient was supposed to get the second dose of the vaccine on 21-May-21. No concomitant drugs were reported. No treatment medications were reported.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Dizziness, Paraesthesia, Presyncope
Clinical narrative: Feeling like she was going to faint; Hands were tingling; Sharp intermittent pain lower right back; Feeling woozy; This spontaneous case was reported by a consumer and describes the occurrence of PRESYNCOPE (Feeling like she was going to faint), PARAESTHESIA (Hands were tingling), BACK PAIN (Sharp intermittent pain lower right back) and DIZZINESS (Feeling woozy) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044AZ1A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jun-2021 at 9:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Jun-2021, the patient experienced PRESYNCOPE (Feeling like she was going to faint), PARAESTHESIA (Hands were tingling) and DIZZINESS (Feeling woozy). 08-Jun-2021, the patient experienced BACK PAIN (Sharp intermittent pain lower right back). At the time of the report, PRESYNCOPE (Feeling like she was going to faint), PARAESTHESIA (Hands were tingling), BACK PAIN (Sharp intermittent pain lower right back) and DIZZINESS (Feeling woozy) outcome was unknown.         Concomitant medications were not reported.  Patient mentioned she received her 2nd dose and was feeling woozy and like she was going to faint. Her hands were tingling and she had a  sharp intermittent pain to lower right back.  Treatment information was not provided.  Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-213261 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Alanine aminotransferase increased, Aspartate aminotransferase increased, Dizziness, Hepatic steatosis, Pain in extremity
Clinical narrative: fatty liver disease; sore arm; little dizziness.; This spontaneous case was reported by a consumer and describes the occurrence of HEPATIC STEATOSIS (fatty liver disease), PAIN IN EXTREMITY (sore arm) and DIZZINESS (little dizziness.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     Concurrent medical conditions included Hepatic steatosis.    On 01-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, the patient experienced PAIN IN EXTREMITY (sore arm) and DIZZINESS (little dizziness.). On 08-Jun-2021, the patient experienced HEPATIC STEATOSIS (fatty liver disease). On 01-Jun-2021, PAIN IN EXTREMITY (sore arm) and DIZZINESS (little dizziness.) outcome was unknown. At the time of the report, HEPATIC STEATOSIS (fatty liver disease) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Jun-2021, Alanine aminotransferase increased: increased (High) Increased values by about 20 points.. On 08-Jun-2021, Aspartate aminotransferase increased: increased (High) Increased values by about 20 points..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product use was reported  No treatment information was provided   Most recent FOLLOW-UP information incorporated above includes: On 05-Aug-2021: Follow-up received: contains Non-significant information.
Sex: U
Vaccine: COVID19
Symptoms: Confusional state, Feeling abnormal, Head discomfort, Myalgia
Clinical narrative: head feels heavy; little befuddlement; feel super foggy; no pain except my arm; This spontaneous case was reported by a patient and describes the occurrence of HEAD DISCOMFORT (head feels heavy), CONFUSIONAL STATE (little befuddlement), FEELING ABNORMAL (feel super foggy) and MYALGIA (no pain except my arm) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HEAD DISCOMFORT (head feels heavy), CONFUSIONAL STATE (little befuddlement), FEELING ABNORMAL (feel super foggy) and MYALGIA (no pain except my arm). At the time of the report, HEAD DISCOMFORT (head feels heavy), CONFUSIONAL STATE (little befuddlement), FEELING ABNORMAL (feel super foggy) and MYALGIA (no pain except my arm) outcome was unknown.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Second dose not received in time window; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second dose not received in time window) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second dose not received in time window). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second dose not received in time window) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant drugs were reported.  Patient reported that there were no side effects with the first dose of the vaccine. The patient was originally scheduled for the second dose of the vaccine on 13-May-2021 but did not get it at that time and had not received that dose till the time of this report. No treatment medications were reported.
Sex: U
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Second shot day passed 10days; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second shot day passed 10days) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second shot day passed 10days). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second shot day passed 10days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Migraine, Rash pruritic, Rosacea, Vomiting
Clinical narrative: Rosacea flare up; Weird vomiting; Little itchy rash patch under my chin; migraine; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RASH PRURITIC (Little itchy rash patch under my chin), MIGRAINE (migraine), ROSACEA (Rosacea flare up) and VOMITING (Weird vomiting) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     The patient's past medical history included Rosacea.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced RASH PRURITIC (Little itchy rash patch under my chin), MIGRAINE (migraine) and VOMITING (Weird vomiting). On 14-Apr-2021, the patient experienced ROSACEA (Rosacea flare up). The patient was treated with HYDROCORTISONE (topical) for Itchy rash, at an unspecified dose and frequency. At the time of the report, RASH PRURITIC (Little itchy rash patch under my chin), MIGRAINE (migraine), ROSACEA (Rosacea flare up) and VOMITING (Weird vomiting) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No relevant concomitant medications were reported.  Patient took advice from her dermatologist and started a three week treatment which included a face cream and low grade antibiotic for rosacea flare up.
Sex: U
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: My armpit to be swollen; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (My armpit to be swollen) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SWELLING (My armpit to be swollen). At the time of the report, SWELLING (My armpit to be swollen) outcome was unknown.            Concomitant product use was not provided by the reporter.  Treatment information was not provided.   Action taken with mRNA-1273 (Moderna COVID-19 Vaccine) in response to the event was not applicable.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Musculoskeletal stiffness, Myalgia, Pain in extremity, Peripheral swelling, Vaccination site pain
Clinical narrative: This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MUSCULOSKELETAL STIFFNESS (left arm is stiff), PERIPHERAL SWELLING (left hand is swollen), PAIN IN EXTREMITY (Both arms were hurting), MYALGIA (both arms were hurting and in one of the visits was told this was just myalgia) and VACCINATION SITE PAIN (pain at the in jection site) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included APIXABAN (ELIQUIS), MEMANTINE and ALUMINIUM HYDROXIDE, MAGNESIUM HYDROXIDE, SIMETICONE (MYLANTA [ALUMINIUM HYDROXIDE;MAGNESIUM HYDROXIDE;SIMETICONE]) for an unknown indication.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Apr-2021, the patient experienced PAIN IN EXTREMITY (Both arms were hurting) and MYALGIA (both arms were hurting and in one of the visits was told this was just myalgia). On 08-Jun-2021, the patient experienced MUSCULOSKELETAL STIFFNESS (left arm is stiff), PERIPHERAL SWELLING (left hand is swollen) and VACCINATION SITE PAIN (pain at the in jection site). The patient was treated with IBUPROFEN at a dose of UNK dosage form; MORPHINE for Pain, at a dose of UNK dosage form; PARACETAMOL (TYLENOL) at a dose of UNK dosage form and TRAMADOL at a dose of UNK dosage form. At the time of the report, MUSCULOSKELETAL STIFFNESS (left arm is stiff), PERIPHERAL SWELLING (left hand is swollen), PAIN IN EXTREMITY (Both arms were hurting), MYALGIA (both arms were hurting and in one of the visits was told this was just myalgia) and VACCINATION SITE PAIN (pain at the in jection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       It was noted by the reporter that the patient had visited the emergency room on three separate occasions for the aforementioned events.  With regards to treatment, it was reported that ibuprofen and morphine were the only treatments that helped from when the patient went to the emergency room.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Excruciating pain in left arm; This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (Excruciating pain in left arm) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     Concomitant products included TRAMADOL, METOPROLOL, METFORMIN and ATORVASTATIN for an unknown indication.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Mar-2021, the patient experienced PAIN IN EXTREMITY (Excruciating pain in left arm). The patient was treated with ACETYLSALICYLIC ACID (ASPRIN) for Pain in arm, at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) for Pain in arm, at an unspecified dose and frequency. On 24-Mar-2021, PAIN IN EXTREMITY (Excruciating pain in left arm) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Products known to have been used by the patient, within two weeks prior to the event, included Vitamins.   This case was linked to MOD-2021-213256 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Slight sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Slight sore arm) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044A21A and 030B21A) for COVID-19 vaccination.     No Medical History information was reported.  Concomitant products included TRAMADOL, METOPROLOL, METFORMIN, ATORVASTATIN and VITAMINS NOS for an unknown indication.   On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Apr-2021, the patient experienced PAIN IN EXTREMITY (Slight sore arm). The patient was treated with ACETYLSALICYLIC ACID (ASPRIN) ongoing since an unknown date for Adverse event, at an unspecified dose and frequency and IBUPROFEN (ADVIL [IBUPROFEN]) ongoing since an unknown date for Adverse event, at an unspecified dose and frequency. On 14-Apr-2021, PAIN IN EXTREMITY (Slight sore arm) had resolved.            Treatment information were not provided.       Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: TCR Doc---Patient said she is doing fine and declined for further follow-up.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Dyspnoea, Pyrexia, Tachycardia
Clinical narrative: Fever of 104; Tachycardia; Shortness of breath; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of TACHYCARDIA (Tachycardia), DYSPNOEA (Shortness of breath) and PYREXIA (Fever of 104) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-May-2021, the patient experienced TACHYCARDIA (Tachycardia) and DYSPNOEA (Shortness of breath). On 12-May-2021, the patient experienced PYREXIA (Fever of 104). At the time of the report, TACHYCARDIA (Tachycardia), DYSPNOEA (Shortness of breath) and PYREXIA (Fever of 104) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 12-May-2021, Body temperature: 104 (High) High. On 13-May-2021, Body temperature: less than 100 (Inconclusive) Stayed under 100.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported.   On 11 May 2021, patient experienced tachycardia and shortness of breath after the first dose of vaccination and went to the emergency room. On 12 May 2021, patient had fever of 104 which went down later and didn't went higher than 100. Again patient went to emergency room and healthcare professional took her off work for week. No treatment information was provided.    This case was linked to MOD-2021-213244 (Patient Link).
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Dysgeusia, Fatigue, Headache, Oropharyngeal pain
Clinical narrative: A fever; Headache; Very fatigued; Joint pain; A curious and bitter tongue that hasn't stopped, mostly in the mornings; She had a sore throat; This spontaneous case was reported by a patient and describes the occurrence of DYSGEUSIA (A curious and bitter tongue that hasn't stopped, mostly in the mornings), OROPHARYNGEAL PAIN (She had a sore throat), PYREXIA (A fever), HEADACHE (Headache) and FATIGUE (Very fatigued) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, the patient experienced OROPHARYNGEAL PAIN (She had a sore throat). On 20-May-2021, the patient experienced DYSGEUSIA (A curious and bitter tongue that hasn't stopped, mostly in the mornings), PYREXIA (A fever), HEADACHE (Headache), FATIGUE (Very fatigued) and ARTHRALGIA (Joint pain). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 20-May-2021, OROPHARYNGEAL PAIN (She had a sore throat), PYREXIA (A fever), HEADACHE (Headache), FATIGUE (Very fatigued) and ARTHRALGIA (Joint pain) had resolved. At the time of the report, DYSGEUSIA (A curious and bitter tongue that hasn't stopped, mostly in the mornings) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Relevant concomitant medications were not provided.  The curious and bitter tongue were not resolved and present mostly in the mornings.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: A fever; Headache; Very fatigued; Joint pain; A curious and bitter tongue that hasn't stopped, mostly in the mornings; She had a sore throat; This spontaneous case was reported by a patient and describes the occurrence of DYSGEUSIA (A curious and bitter tongue that hasn't stopped, mostly in the mornings), OROPHARYNGEAL PAIN (She had a sore throat), PYREXIA (A fever), HEADACHE (Headache) and FATIGUE (Very fatigued) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-May-2021, the patient experienced OROPHARYNGEAL PAIN (She had a sore throat). On 20-May-2021, the patient experienced DYSGEUSIA (A curious and bitter tongue that hasn't stopped, mostly in the mornings), PYREXIA (A fever), HEADACHE (Headache), FATIGUE (Very fatigued) and ARTHRALGIA (Joint pain). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 20-May-2021, OROPHARYNGEAL PAIN (She had a sore throat), PYREXIA (A fever), HEADACHE (Headache), FATIGUE (Very fatigued) and ARTHRALGIA (Joint pain) had resolved. At the time of the report, DYSGEUSIA (A curious and bitter tongue that hasn't stopped, mostly in the mornings) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Relevant concomitant medications were not provided.  The curious and bitter tongue were not resolved and present mostly in the mornings.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Sex: U
Vaccine: COVID19
Symptoms: Hypoacusis
Clinical narrative: hard time hearing; This spontaneous case was reported by a consumer and describes the occurrence of HYPOACUSIS (hard time hearing) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HYPOACUSIS (hard time hearing). At the time of the report, HYPOACUSIS (hard time hearing) outcome was unknown.            No relevant concomitant medications were reported.  No treatment details were reported.
Age: 80.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient received the second dose 8 days before; This spontaneous case was reported by a health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the second dose 8 days before) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017C21A and 001C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 19-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 08-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the second dose 8 days before). On 08-Jun-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient received the second dose 8 days before) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   On 08-Jun-2021, the patient received their second dose. The patient received their first dose on 19-May-2021 and came 8 days early for their second dose. The reporter also mentioned that the patient was taking other medication and was not aware of the patient's symptoms.  Concomitant product use was not provided by the reporter.   ? No treatment information was provided. ? The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the mRNA-1273 in response to the events was not applicable. ?
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration, Vaccination site pain, Vaccination site pruritus, Vaccination site warmth
Clinical narrative: Itching hot spot; second dose was outside the recommended dosing interval; Itching hot spot; pain at the injection site on left arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (Itching hot spot), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was outside the recommended dosing interval), VACCINATION SITE PRURITUS (Itching hot spot) and VACCINATION SITE PAIN (pain at the injection site on left arm) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Mar-2021, the patient experienced VACCINATION SITE PAIN (pain at the injection site on left arm). On 28-May-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE WARMTH (Itching hot spot), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was outside the recommended dosing interval) and VACCINATION SITE PRURITUS (Itching hot spot). On 08-Mar-2021, VACCINATION SITE PAIN (pain at the injection site on left arm) had resolved. On 28-May-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose was outside the recommended dosing interval) had resolved. On 02-Jun-2021, VACCINATION SITE WARMTH (Itching hot spot) and VACCINATION SITE PRURITUS (Itching hot spot) had resolved.            Action taken with mRNA-1273 in response to the events was not Applicable. Concomitant and treatment information not provided   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Patient demographics, event verbatim was added.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Feeling hot, Hyperhidrosis, Nasopharyngitis, Pyrexia
Clinical narrative: Feels like I have a cold; Sweaty; Hot; Sneezing; Oral Temperature of 98 Degrees F; This spontaneous case was reported by a patient and describes the occurrence of NASOPHARYNGITIS (Feels like I have a cold), HYPERHIDROSIS (Sweaty), FEELING HOT (Hot), SNEEZING (Sneezing) and PYREXIA (Oral Temperature of 98 Degrees F) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C2119) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included CETIRIZINE for Allergy, MULTIVITAMINS [VITAMINS NOS] and VIT D [VITAMIN D NOS] for an unknown indication.    On 06-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jun-2021, the patient experienced NASOPHARYNGITIS (Feels like I have a cold), HYPERHIDROSIS (Sweaty), FEELING HOT (Hot), SNEEZING (Sneezing) and PYREXIA (Oral Temperature of 98 Degrees F). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form. At the time of the report, NASOPHARYNGITIS (Feels like I have a cold), HYPERHIDROSIS (Sweaty), FEELING HOT (Hot), SNEEZING (Sneezing) and PYREXIA (Oral Temperature of 98 Degrees F) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Jun-2021, Body temperature: 98 (High) oral temperature of 98 degrees F ( patient's baseline temperature is reportedly 97 degrees F).     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Sneezing
Clinical narrative: Feels like I have a cold; Sweaty; Hot; Sneezing; Oral Temperature of 98 Degrees F; This spontaneous case was reported by a patient and describes the occurrence of NASOPHARYNGITIS (Feels like I have a cold), HYPERHIDROSIS (Sweaty), FEELING HOT (Hot), SNEEZING (Sneezing) and PYREXIA (Oral Temperature of 98 Degrees F) in a 40-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C2119) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included CETIRIZINE for Allergy, MULTIVITAMINS [VITAMINS NOS] and VIT D [VITAMIN D NOS] for an unknown indication.    On 06-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jun-2021, the patient experienced NASOPHARYNGITIS (Feels like I have a cold), HYPERHIDROSIS (Sweaty), FEELING HOT (Hot), SNEEZING (Sneezing) and PYREXIA (Oral Temperature of 98 Degrees F). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form. At the time of the report, NASOPHARYNGITIS (Feels like I have a cold), HYPERHIDROSIS (Sweaty), FEELING HOT (Hot), SNEEZING (Sneezing) and PYREXIA (Oral Temperature of 98 Degrees F) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Jun-2021, Body temperature: 98 (High) oral temperature of 98 degrees F ( patient's baseline temperature is reportedly 97 degrees F).     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Blood pressure measurement, Flushing, Sleep disorder, Vaccination site pain
Clinical narrative: arm pain/ slight upper arm soreness; Disturbed sleep; Slightly flushness through my body; This spontaneous case was reported by a consumer and describes the occurrence of SLEEP DISORDER (Disturbed sleep), FLUSHING (Slightly flushness through my body) and PAIN IN EXTREMITY (arm pain/ slight upper arm soreness) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     The patient's past medical history included Coronary artery anomaly, congenital (at the age of 49). Family history included Stent placement in 1972 and Cardiac disorder (Patient's father has a quadruple bypass surgery at 61 and stent placement at 82 years of age.). Concurrent medical conditions included Cardiovascular risk and Obesity (slightly over weight). Concomitant products included VITAMIN D3, ARGININE HYDROCHLORIDE (L ARGININ), NICOTINAMIDE RIBOSIDE (TRU NIAGEN), L-CITRULLINE and RESVERATROL for an unknown indication.    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm pain/ slight upper arm soreness). On an unknown date, the patient experienced SLEEP DISORDER (Disturbed sleep) and FLUSHING (Slightly flushness through my body). The patient was treated with IBUPROFEN at an unspecified dose and frequency; MAGNESIUM at a dose of 1600 mg; ACETYLSALICYLIC ACID (ASPRIN) at a dose of 80 milligram once a day and MELATONIN at a dose of 40 milligram per week. At the time of the report, SLEEP DISORDER (Disturbed sleep), FLUSHING (Slightly flushness through my body) and PAIN IN EXTREMITY (arm pain/ slight upper arm soreness) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: 120/72 (normal) Treated and 138/85 (Inconclusive) Untreated blood pressure.     mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       This case was linked to MOD-2021-213281 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 02-Jul-2021: Updated patient medical history and added concomitant medication.
Sex: U
Vaccine: COVID19
Symptoms: Rash macular
Clinical narrative: large red blemishes on my legs; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (large red blemishes on my legs) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) unknown. On an unknown date, the patient experienced RASH MACULAR (large red blemishes on my legs). At the time of the report, RASH MACULAR (large red blemishes on my legs) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.   Reporter did not allow further contact
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Malaise, Myalgia
Clinical narrative: Malaise; Achy; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (Malaise) and MYALGIA (Achy) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     Concurrent medical conditions included Anxiety. Concomitant products included CLONAZEPAM for Anxiety, AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) for an unknown indication.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced MALAISE (Malaise) and MYALGIA (Achy). On 09-Apr-2021, MALAISE (Malaise) outcome was unknown. At the time of the report, MYALGIA (Achy) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Concomitant medications included birth control pills.  Patient was treated with anti-nausea medication, IV fluids, IV potassium  Patient took second dose of on 05-MAY-2021.   This case was linked to MOD-2021-213293 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Chest discomfort, Dyspnoea
Clinical narrative: Difficulty breathing; Tightness of chest; This spontaneous case was reported by a consumer and describes the occurrence of CHEST DISCOMFORT (Tightness of chest) and DYSPNOEA (Difficulty breathing) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CHEST DISCOMFORT (Tightness of chest) and DYSPNOEA (Difficulty breathing). At the time of the report, CHEST DISCOMFORT (Tightness of chest) and DYSPNOEA (Difficulty breathing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  No treatment information was provided.
Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue, Vaccination site erythema
Clinical narrative: Did not receive second dose; Redness at injection site; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Did not receive second dose) and VACCINATION SITE ERYTHEMA (Redness at injection site) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     The patient's past medical history included Hypertension since an unknown date. Concomitant products included IRBESARTAN, CARVEDILOL and CLONIDINE for Hypertension, ASPIRIN [ACETYLSALICYLIC ACID] for Prophylaxis.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at injection site). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Did not receive second dose). On 18-Jan-2021, VACCINATION SITE ERYTHEMA (Redness at injection site) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (Did not receive second dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided.
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: Sore arm; Dizziness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm) and DIZZINESS (Dizziness) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high. Concomitant products included TADALAFIL (CIALIS), LISINOPRIL, GLIMEPIRIDE, METFORMIN, TIZANIDINE, TRAMADOL and CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) for an unknown indication.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm) and DIZZINESS (Dizziness). At the time of the report, PAIN IN EXTREMITY (Sore arm) and DIZZINESS (Dizziness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications provided by the reporter.  For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments